GoodRx Holdings (GDRX) Receivables (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Receivables data on file, last reported at $244.6 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 52.78% year-over-year to $244.6 million; the trailing twelve-month figure through Mar 2026 stood at $244.6 million (up 52.78% YoY), and the FY2025 full-year result was $247.6 million, up 69.7% from the prior year.
• Receivables declined to $244.6 million in Q1 2026, from $247.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $247.6 million in Q4 2025 to a low of $116.4 million in Q1 2023.
• A 5-year average of $154.0 million and a median of $143.6 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables slipped 5.55% in 2023 and soared 69.7% in 2025, its largest moves.
• Tracing GDRX's Receivables over 5 years: stood at $117.1 million in 2022, then rose by 22.59% to $143.6 million in 2023, then advanced by 1.62% to $145.9 million in 2024, then soared by 69.7% to $247.6 million in 2025, then fell by 1.22% to $244.6 million in 2026.
• Business Quant data shows GDRX's Receivables at $244.6 million in Q1 2026, $247.6 million in Q4 2025, and $203.7 million in Q3 2025.